|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2
|
Schwartz K, Powell IJ, Underwood W III, et
al: Interplay of race, socioeconomic status and treatment on
survival of patients with prostate cancer. Urology. 74:1296–1302.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Williams H and Powell IJ: Epidemiology,
pathology and genetics of prostate cancer among African Americans
compared with other ethnicities. Methods Mol Biol. 472:439–453.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Martin DN, Starks AM and Ambs S:
Biological determinants of health disparities in prostate cancer.
Curr Opin Oncol. 25:235–241. 2013.PubMed/NCBI
|
|
5
|
Farrell J, Petrovics G, McLeod DG and
Srivastava S: Genetic and molecular differences in prostate
carcinogenesis between African American and Caucasian American men.
Int J Mol Sci. 14:15510–15531. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tomlins SA, Rhodes DR, Perner S, et al:
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in
prostate cancer. Science. 310:644–648. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Petrovics G, Liu A, Shaheduzzaman S, et
al: Frequent overexpression of ETS-related gene-1 (ERG1) in
prostate cancer transcriptome. Oncogene. 24:3847–3852. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rubin MA, Maher CA and Chinnaiyan AM:
Common gene rearrangements in prostate cancer. J Clin Oncol.
29:3659–3668. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Barbieri CE, Bangma CH, Bjartell A, et al:
The mutational landscape of prostate cancer. Eur Urol. 64:567–576.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu Y, Dobi A, Sreenath T, et al:
Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin
Cancer Res. 14:4719–4725. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rice KR, Chen Y, Ali A, et al: Evaluation
of the ETS-related gene mRNA in urine for the detection of prostate
cancer. Clin Cancer Res. 16:1572–1576. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Magi-Galluzzi C, Tsusuki T, Elson P, et
al: TMPRSS2-ERG gene fusion prevalence and class are significantly
different in prostate cancer of Caucasian, African-American and
Japanese patients. Prostate. 71:489–497. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rosen P, Pfister D, Young D, et al:
Differences in frequency of ERG oncoprotein expression between
index tumors of Caucasian and African American patients with
prostate cancer. Urology. 80:749–753. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Furusato B, Tan SH, Young D, et al: ERG
oncoprotein expression in prostate cancer: clonal progression of
ERG-positive tumor cells and potential for ERG-based
stratification. Prostate Cancer Prostatic Dis. 13:228–237. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park K, Tomlins SA, Mudaliar KM, et al:
Antibody-based detection of ERG rearrangement-positive prostate
cancer. Neoplasia. 12:590–598. 2010.PubMed/NCBI
|
|
16
|
Braun M, Goltz D, Shaikhibrahim Z, et al:
ERG protein expression and genomic rearrangement status in primary
and metastatic prostate cancer - a comparative study of two
monoclonal antibodies. Prostate Cancer Prostatic Dis. 15:165–169.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rosen P, Sesterhenn IA, Brassell SA, et
al: Clinical potential of the ERG oncoprotein in prostate cancer.
Nat Rev Urol. 9:131–137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brassell SA, Rice KR, Parker PM, et al:
Prostate cancer in men 70 years old or older, indolent or
aggressive: clinicopathological analysis and outcomes. J Urol.
185:132–137. 2011.PubMed/NCBI
|
|
19
|
Brimo F, Montironi R, Egevad L, et al:
Contemporary grading for prostate cancer: implications for patient
care. Eur Urol. 63:892–901. 2013. View Article : Google Scholar : PubMed/NCBI
|
